Thursday 16 October, 2025
Objectives: Neutralizing monoclonal antibodies (mAb) to provide novel therapeutics for COVID-19 treatment, were urgently researched from the start of the…
Read morePoster: Drug/Disease Modelling - COVID-19
Antiviral Treatment on SARS-Cov-2 Infected Epithelial Tissue Patch
Thursday 16 October, 2025
Objective: Developing antiviral drugs and neutralizing antibodies to treat SARS-CoV-2 infection are currently emerging, and several clinical trials are ongoing…
Read moreDeveloping a model of SARS-CoV-2 viral dynamics under monoclonal antibody treatment.
Thursday 16 October, 2025
Introduction: After more than a year of an unprecedented pandemic, it remains critical to find effective anti-viral strategies against SARS-CoV-2…
Read moreModeling changes in SARS-CoV-2 variants within-host transmissibility on antiviral drug effect
Thursday 16 October, 2025
Introduction: As of May 2021, no antiviral drug regimen has proved effective against SARS-CoV-2. With the pandemic showing no signs of…
Read moreTherapeutic effect of anti-IL6 monoclonal antibodies in the treatment of COVID-19 in adults and multisystem inflammatory syndrome in children using siltuximab as a case study
Thursday 16 October, 2025
Introduction: At the beginning of the COVID-19 pandemics, it seemed that infected children were asymptomatic, or likely to develop only…
Read moreTowards fixed dosing of tocilizumab in ICU admitted COVID-19 patients; results of an observational population pharmacokinetic and descriptive pharmacodynamic study
Thursday 16 October, 2025
Introduction: The inflammatory storm associated with severe acute respiratory syndrome coronavirus 2 infection damages the respiratory tract and causes high…
Read moreApplication of modelling and simulation in development of an antibody cocktail for the prevention and treatment of COVID-19
Thursday 16 October, 2025
Introduction: AZD7442, a combination product of 2 mAbs (AZD8895 and AZD1061), is being studied for the prophylaxis and treatment of…
Read more